An Overview of Novel Dietary Supplements and Food Ingredients in Patients with Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2018 Apr 12

PMID 29641459

Citations 17

Authors

Priscila Silva Figueiredo

Aline Carla Inada

Melina Ribeiro Fernandes

Daniela Granja Arakaki

Karine de Cassia Freitas

Rita de Cassia Avellaneda Guimaraes

Valter Aragao do Nascimento

Priscila Aiko Hiane

Affiliations

Soon will be listed here.

Abstract

Metabolic syndrome (MetS) is characterized by interconnected factors related to metabolic disturbances, and is directly related to the occurrence of some diseases such as cardiovascular diseases and type 2 diabetes. MetS is described as one or both of insulin resistance and visceral adiposity, considered the initial causes of abnormalities that include hyperglycemia, elevated blood pressure, dyslipidemia, elevated inflammatory markers, and prothrombotic state, as well as polycystic ovarian syndrome in women. Other than in MetS, visceral adiposity and the pro-inflammatory state are also key in the development of non-alcoholic fatty liver disease (NAFLD), which is the most prevalent chronic liver disease in modern society. Both MetS and NAFLD are related to diet and lifestyle, and their treatment may be influenced by dietary pattern changes and the use of certain dietary supplements. This study aimed to review the role of food ingredients and supplements in the management of MetS and NAFLD specifically in human clinical trials. Moreover, bioactive compounds and polyunsaturated fatty acids (PUFAs) may be used as strategies for preventing the onset of and treatment of metabolic disorders, such as MetS and NAFLD, improving the inflammatory state and other comorbidities, such as obesity, dyslipidemias, and cardiovascular diseases (CVD).

Citing Articles

Natural Bioactive Compounds in the Management of Type 2 Diabetes and Metabolic (Dysfunction)-Associated Steatotic Liver Disease.

Ciobarca D, Catoi A, Gavrilas L, Banc R, Miere D, Filip L Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006091 PMC: 11859434. DOI: 10.3390/ph18020279.

Antioxidant Peptides from Miiuy Croaker Swim Bladders: Ameliorating Effect and Mechanism in NAFLD Cell Model through Regulation of Hypolipidemic and Antioxidant Capacity.

Wang Y, Ge M, Ran S, Pan X, Chi C, Wang B Mar Drugs. 2025; 23(2).

PMID: 39997187 PMC: 11857530. DOI: 10.3390/md23020063.

Global hotspots and trends of nutritional supplements for sick populations from 2000 to 2024.

Shi C, Liu H, Fu T, Li Y, Zhao H, Liu F Front Nutr. 2025; 12:1497207.

PMID: 39935585 PMC: 11810749. DOI: 10.3389/fnut.2025.1497207.

Effects of resveratrol supplementation on serum concentrations of plasminogen activator inhibitor-1, fibroblast growth factor 21, and adiponectin in patients with nonalcoholic fatty liver disease.

Farzin L, Mansouri E, Salehi S, Baker E, Amirkhizi F, Asghari S BMC Nutr. 2025; 11(1):36.

PMID: 39930480 PMC: 11809030. DOI: 10.1186/s40795-025-00997-4.

Suppression of the postprandial hyperglycemia in patients with type 2 diabetes by a raw medicinal herb powder is weakened when consumed in ordinary hard gelatin capsules: A randomized crossover clinical trial.

Moreira F, Reis C, Gallassi A, Moreira D, Welker A PLoS One. 2024; 19(10):e0311501.

PMID: 39383145 PMC: 11463819. DOI: 10.1371/journal.pone.0311501.

References

Takahashi Y, Sugimoto K, Inui H, Fukusato T . Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2015; 21(13):3777-85. PMC: 4385525. DOI: 10.3748/wjg.v21.i13.3777. View

Jump D, Lytle K, Depner C, Tripathy S . Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease. Pharmacol Ther. 2017; 181:108-125. PMC: 5743581. DOI: 10.1016/j.pharmthera.2017.07.007. View

Rajaram S, Baylink D, Mohan S . Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev. 1997; 18(6):801-31. DOI: 10.1210/edrv.18.6.0321. View

Venturini D, Simao A, Urbano M, Dichi I . Effects of extra virgin olive oil and fish oil on lipid profile and oxidative stress in patients with metabolic syndrome. Nutrition. 2015; 31(6):834-40. DOI: 10.1016/j.nut.2014.12.016. View

Dasarathy J, Varghese R, Feldman A, Khiyami A, McCullough A, Dasarathy S . Patients with Nonalcoholic Fatty Liver Disease Have a Low Response Rate to Vitamin D Supplementation. J Nutr. 2017; 147(10):1938-1946. PMC: 5610550. DOI: 10.3945/jn.117.254292. View

Bozzetto L, Prinster A, Annuzzi G, Costagliola L, Mangione A, Vitelli A . Liver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patients. Diabetes Care. 2012; 35(7):1429-35. PMC: 3379578. DOI: 10.2337/dc12-0033. View

Beilfuss J, Berg V, Sneve M, Jorde R, Kamycheva E . Effects of a 1-year supplementation with cholecalciferol on interleukin-6, tumor necrosis factor-alpha and insulin resistance in overweight and obese subjects. Cytokine. 2012; 60(3):870-4. DOI: 10.1016/j.cyto.2012.07.032. View

Zhao L, Guo X, Wang O, Zhang H, Wang Y, Zhou F . Fructose and glucose combined with free fatty acids induce metabolic disorders in HepG2 cell: A new model to study the impacts of high-fructose/sucrose and high-fat diets in vitro. Mol Nutr Food Res. 2016; 60(4):909-21. DOI: 10.1002/mnfr.201500635. View

Humphries S, Talmud P, Hawe E, Bolla M, Day I, Miller G . Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study. Lancet. 2001; 358(9276):115-9. DOI: 10.1016/S0140-6736(01)05330-2. View

10.

Aziz Z, Wong S, Chong N . Effects of Hibiscus sabdariffa L. on serum lipids: a systematic review and meta-analysis. J Ethnopharmacol. 2013; 150(2):442-50. DOI: 10.1016/j.jep.2013.09.042. View

11.

Shaw K, Gennat H, ORourke P, Del Mar C . Exercise for overweight or obesity. Cochrane Database Syst Rev. 2006; (4):CD003817. PMC: 9017288. DOI: 10.1002/14651858.CD003817.pub3. View

12.

Mozaffarian D, Wu J . Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011; 58(20):2047-67. DOI: 10.1016/j.jacc.2011.06.063. View

13.

Orchard T, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S . The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005; 142(8):611-9. PMC: 2505046. DOI: 10.7326/0003-4819-142-8-200504190-00009. View

14.

Salekzamani S, Mehralizadeh H, Ghezel A, Salekzamani Y, Jafarabadi M, Bavil A . Effect of high-dose vitamin D supplementation on cardiometabolic risk factors in subjects with metabolic syndrome: a randomized controlled double-blind clinical trial. J Endocrinol Invest. 2016; 39(11):1303-1313. DOI: 10.1007/s40618-016-0507-8. View

15.

Holick M . Vitamin D deficiency. N Engl J Med. 2007; 357(3):266-81. DOI: 10.1056/NEJMra070553. View

16.

Kris-Etherton P, PEARSON T, Wan Y, HARGROVE R, Moriarty K, Fishell V . High-monounsaturated fatty acid diets lower both plasma cholesterol and triacylglycerol concentrations. Am J Clin Nutr. 1999; 70(6):1009-15. DOI: 10.1093/ajcn/70.6.1009. View

17.

Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, Ghosh S . MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell. 1998; 2(2):253-8. DOI: 10.1016/s1097-2765(00)80136-7. View

18.

Simopoulos A . Evolutionary aspects of diet and essential fatty acids. World Rev Nutr Diet. 2002; 88:18-27. DOI: 10.1159/000059742. View

19.

Chen S, Zhao X, Ran L, Wan J, Wang X, Qin Y . Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial. Dig Liver Dis. 2015; 47(3):226-32. DOI: 10.1016/j.dld.2014.11.015. View

20.

Egert S, Bosy-Westphal A, Seiberl J, Kurbitz C, Settler U, Plachta-Danielzik S . Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study. Br J Nutr. 2009; 102(7):1065-74. DOI: 10.1017/S0007114509359127. View